Blog
RSS FeedPosted by Michael Wonder on 14 Jan 2019
Cost recovery and Pharmaceutical Benefits Scheme process improvements information forums
14 January 2019 - The Department of Health will be hosting information forums in both Sydney and Melbourne regarding amendments ...
Posted by Michael Wonder on 13 Jan 2019
China has a very unhealthy interest in our medical data
14 January 2019 - Chinese companies are required by law to obey directives from Beijing's intelligence agencies. So why would ...
Posted by Michael Wonder on 13 Jan 2019
The impact of moving from the EQ-5D-3L to the -5L in NICE technology appraisals
11 January 2019 - The EQ-5D instrument is NICE’s preferred measure of health-related quality of life in adults. ...
Posted by Michael Wonder on 11 Jan 2019
PBS Expenditure and Prescriptions Report 2017-18
11 January 2019 - The PBS Expenditure and Prescriptions Report 2017-18 is now available. ...
Posted by Michael Wonder on 11 Jan 2019
Notification of decision involving treatments for multiple sclerosis, narcolepsy, and attention deficit hyperactivity disorder
11 January 2019 - PHARMAC is pleased to announce the approval of a multi-product agreement with Teva Pharma New Zealand ...
Posted by Michael Wonder on 10 Jan 2019
2018 in a nutshell: new edition with facts and graphics from the IQWiG
9 January 2019 - The focus of the 33-page brochure is information, overviews and charts on "Health Technology Assessment (HTA) ...
Posted by Michael Wonder on 10 Jan 2019
NICE publishes final guidance on another use of Keytruda for patients with NSCLC
10 January 2019 - This time it is for patients with untreated, metastatic non-squamous non-small cell lung cancer. ...
Posted by Michael Wonder on 10 Jan 2019
New migraine drug not cost-effective NICE says in draft guidance
10 January 2019 - NICE has said that a new drug for preventing migraine is not a cost effective use of ...
Posted by Michael Wonder on 10 Jan 2019
Decision to list a new presentation of raltegravir and amend arrangements for raltegravir and posaconazole
10 January 2019 - PHARMAC is pleased to announce its decision to approve a multi-product agreement with Merck Sharpe & ...
Posted by Michael Wonder on 09 Jan 2019
PBAC - 2018 in review (cancer)
10 January 2019 - The PBAC considered many submissions for new cancer medicines (new medicine, new indication and new combination ...
Posted by Michael Wonder on 09 Jan 2019
NICE publishes final guidance on the use of darvadstrocel on the NHS
9 January 2019 - The Department of Health and Social Care has asked the NICE to produce guidance on the use ...
Posted by Michael Wonder on 09 Jan 2019
Stivarga final NICE recommendation for hepatocellular carcinoma
9 January 2019 - Bayer’s Stivarga has received a final green light from NICE for use by the NHS to ...
Posted by Michael Wonder on 07 Jan 2019
Paying it forward: man pledges $1million to get life-saving cancer treatment in NZ
31 December 2018 - The Herald speaks with Kiwis who have been on the edge of death, had their world ...
Posted by Michael Wonder on 07 Jan 2019
PBAC - 2018 in review
7 January 2019 - The PBAC considered 195 submissions in 2018; 173 were considered by the PBAC in 2017. ...
Posted by Michael Wonder on 04 Jan 2019
Decision criteria that influence managed entry agreements
3 January 2019 - Managed entry agreements enable payers to subsidise access to new medicines while addressing uncertainties. ...